Plenary Session

Latest Episodes:

1.14 BONUS! Immunotherapy in Desperation and the Pennington Lecture: Myths of Medicine and Marketing Oct 12, 2018

Show notes

This BONUS episode is the recording of the 22nd annual Pennington Lecture given at Oregon Health & Science University on September 21, 2018. The lecture is on seven myths of medicine and marketing. Before the lecture we read and discuss the editorial "Desperation Oncology" by Tito Fojo, published in Seminars in Oncology.

1.13 KEYNOTE-189, Dr. Talal Hilal on MRD, and Medical Education with Dr. Adam Cifu Oct 08, 2018

Show notes

Listen in for a breakdown of the good and the bad of KEYNOTE-189(trial published in NEJM), a discussion with Dr. Talal Hilal of the Mayo Clinic on the rise of minimal residual disease as a clinical endpoint, and an interview with Dr. Adam Cifu of the University of Chicago Pritzker School of Medicine on medical education, sham trials, and more.

1.12 BONUS! Evidence-Based Medicine Has Been Hijacked in Oncology Oct 03, 2018

Show notes

This BONUS episode is the recording of a Grand Rounds talk given at Oregon Health & Science University on September 19, 2018. The talk was inspired by the article by JPA Ioannidis titled "Evidence-based medicine has been hijacked: a report to David Sackett", published May 2016 in the Journal of Clinical Epidemiology.

1.11 Peanut Gallery, Research Parasites, Appendectomies, HRQoL and PFS, Dr. Bishal Gyawali Oct 02, 2018

Show notes

We discuss Dr. Califf's comment on the "social media peanut gallery of experts", Dr. Drazen's comment on "research parasites" and his retirement from NEJM, the recent paper in JAMA on long-term follow up for antibiotics as compared to appendectomies, and the paper in JAMA Internal Medicine on the relationship between health-related quality of life and progression-free survival. Finally, we interview Dr. Bishal Gyawali on a variety of topics, including cancer groundshot.

1.10 Criticism via Twitter, PACIFIC, PCI for CAD, and Dr. Rebecca Cooney of The Lancet Sep 25, 2018

Show notes

Today we tackle some cardiologists' opposition to criticizing clinical trials on Twitter, the PACIFIC trial on durvalumab in stage III non–small-cell lung cancer, and the recent paper in Heart: "Percutaneous Coronary Intervention for Stable Coronary Artery Disease" by R.K. Al-Lamee, A.N. Nowbar, and D.P. Francis. We end with an interview on academic medical publishing with Dr. Rebecca Cooney, North American Executive Editor of The Lancet.

1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints Sep 20, 2018

Show notes

Special episode! We discuss the recent correspondence in NEJM on response rate in phase I clinical trials, the JACOB trial published in The Lancet Oncology on pertuzumab for HER2-positive gastric cancer, and we give an evaluation of MI, stroke, and metastasis as hard endpoints.

1.08 Hyperprolific authors, NCCN with Jeff Wagner, and Dr. Renee Dversdal on Ultrasounds Sep 14, 2018

Show notes

In this episode we discuss hyperprolific authors and the recent comment in Nature by JPA Ioannidis, R Klavans, & KW Boyack; NCCN guidelines with fourth-year medical student Jeffrey Wagner; and point-of-care ultrasounds with Dr. Renee Dversdal of OHSU.

1.07 Adjuvant Sunitinib in RCC, future of EBM with Dr. John Mandrola Sep 11, 2018

Show notes

In this episode we discuss the USA FDA's recent approval of sunitinib as the adjuvant treatment for patients with resected renal cell carcinoma who are at high risk of relapse. We also interview cardiologist Dr. John Mandrola on new directions forward for evidence-based medicine.

1.06 RELEVANCE, Jenny Gill, and Dr. Catherine Livingston of the Oregon Health Authority Sep 07, 2018

Show notes

In this episode we break down the RELEVANCE trial published in the New England Journal of Medicine; discuss big data in observational studies with Jenny Gill, MS; and interview Dr. Catherine Livingston of OHSU, an expert in healthcare policy, on her work with the Oregon Health Authority and state Medicaid.

1.05 Cost and Efficacy of Cancer Drugs, ECHELON-1, Dr. Derrick Tao, and EBM with Dr. Martha Gerrity Sep 05, 2018

Show notes

In this episode we cover the cost and efficacy of cancer drugs; review ECHELON-1; interview Dr. Derrick Tao of OHSU about his recent Lancet Oncology paper on poor control arms; and discuss evidence-based medicine with EBM expert and internist at OHSU, Dr. Martha Gerrity.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected